Salute e Benessere

Valneva Reports High Sustained Immune Response in Adolescents One Year After…

Saint-Herblain (France), January 20, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination. These results support and strengthen the pivotal data previously reported for adolescents (12 to 17 years old) which supported filing for potential label...
Nasdaq GlobeNewswire
20/01/2025

MedTech Industry to Hit USD 694.7 Billion by 2025 with ~4% CAGR |…

Browse in-depth TOC on "MedTech Market" Browse in-depth TOC on "MedTech Market" 15 - Tables 10 - Figures 45 - Pages The Global MedTech Industry Outlook for 2025 aims to provide insights into the anticipated performance of the MedTech sectors, covering recent advancements in imaging technologies and the development of innovative surgical solutions. The report will assess the industry's performance in 2024 relative to 2023 and highlight the significant breakthroughs and…
PR Newswire
20/01/2025

Single Use Assemblies Market to Hit USD 4.89 Billion by 2029 with 13.2% CAGR |…

Browse in-depth TOC on "Single Use Assemblies Market"470 - Tables58 - Figures427 - Pages Browse in-depth TOC on "Single Use Assemblies Market" 470 - Tables 58 - Figures 427 - Pages The market for single-use assemblies has experienced significant growth also due to increasing investments in biopharmaceutical R&D, and growing demand for outsourcing services. The growing demand for biologics, such as monoclonal antibodies, vaccines, and others, is a major factor contributing…
PR Newswire
20/01/2025

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 20 January 2025– On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under…
Nasdaq GlobeNewswire
20/01/2025

RAMSAY SANTE :repricing launch 20 01 2025

PRESS RELEASE Paris, 20 January 2025 Ramsay Santé launches the repricing of its €1,025m TLB4 due 2031On 13 August 2024, Ramsay Santé closed an Amend & Extend of its €1,650m Senior Debt facilities, including a €1,025m 7-year TLB4 priced at E+400bps.On the back of currently favorable market conditions, Ramsay Santé is now looking to reprice its €1,025m TLB4. This transaction is arranged by BNP Paribas and Crédit Agricole CIB as Physical Bookrunners.The completion of the...
Nasdaq GlobeNewswire
20/01/2025

SIRPAD - WORLD'S LARGEST RCT INVESTIGATING MAGICTOUCH PTA SIROLIMUS COATED…

More than 1,250 patients have been enrolled and will be followed up at 12 months to assess the primary outcome of major adverse limb events (MALE). Final results are expected by Q1-Q2 2026. More than 1,250 patients have been enrolled and will be followed up at 12 months to assess the primary outcome of major adverse limb events (MALE). Final results are expected by Q1-Q2 2026. SirPAD is an investigator-initiated, multi-centre, randomized, open-label trial that aims to determine whether the...
PR Newswire
20/01/2025

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for…

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of multiple malignant tumors. To date, toripalimab has been approved for marketing in over 35 countries and regions around the world. In 2024, toripalimab received approvals from both the European Commission (EC) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the following indications: 1) in combination with cisplatin and gemcitabine for the...
Nasdaq GlobeNewswire
20/01/2025

Immunovia AB announces outcome of exercise of warrants series TO 2

"We are thankful and appreciate the investment in Immunovia by those who exercised warrants. We will utilize this capital to prepare for the introduction of our next-generation test to the US market later this year. These funds will be used to generate additional clinical data to support test reimbursement." "We are thankful and appreciate the investment in Immunovia by those who exercised warrants. We will utilize this capital to prepare for the introduction of our…
PR Newswire
20/01/2025

The Best Valentine's Day Gift Ideas 2025: DermRays V8S - The Only Unisex Home…

What sets the DermRays V8S apart from other products on the market is its unisex appeal. Whether for your partner, spouse, or a special someone, this device provides a luxury experience that both men and women will appreciate. No longer are beauty treatments confined to one gender-this device brings equal benefits to everyone, making it the perfect gift for couples who enjoy sharing their wellness routines. What sets the DermRays V8S apart from other products on the market is its unisex…
PR Newswire
20/01/2025

Segra International and GreenBe Pharma Forge a Partnership to Streamline Access…

Award-Winning Tissue Culture Clones Now Locally Available, Simplifying European Cultivators' Supply Chain Segra International(“Segra”), a globally recognized leader in cannabis ag-tech and genetics, is pleased to announce a strategic partnership withGreenBe Pharma, a premier European medicinal cannabis producer. This collaboration enables European cultivators to efficiently access Segra's renowned tissue culture cannabis clones through a localized European hub, significantly reducing...
Nasdaq GlobeNewswire
20/01/2025

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 20, 2025– Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052,...
Nasdaq GlobeNewswire
20/01/2025

Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement…

Dr. Deco Deng, Founder of Fermion, stated: "We are delighted to partner with Simcere, a leading pharmaceutical company. As the first domestically developed and the world's second high-selectivity SSTR4 agonist to enter the clinical stage, FZ002-037 holds great promise. By leveraging Simcere's strong development and commercialization capabilities, we are confident in accelerating its progress to provide better treatment options for patients suffering from pain." Dr. Deco Deng, Founder…
PR Newswire
18/01/2025

MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney…

The TGFR is validated for use in the assessment of Glomerular Filtration Rate (GFR) in patients with stable kidney function at the point of care. The TGFR utilizes an intravenous Lumitrace injection but does not require blood draws or urine analysis, unlike current methodologies requiring multiple blood draws or urine samples. In addition, current clinical practice measured GFR (mGFR) assessment requires sophisticated clinical laboratory analysis away from the patient's point of care. The…
PR Newswire
18/01/2025

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

VANCOUVER, BC, Jan. 17, 2025 /PRNewswire/ -- According to experts, soon the integration of artificial intelligence (AI) into healthcare will drastically shift from a novelty, to a critical resource. With over 800 FDA-cleared health AI applications, the new expectation is that AI will be a game changer. In a new article from Fast Company, the author predicts health AI in 2025 will include home testing, AI agents, passive monitoring, ambient documentation, and autonomous coding. The World Economic…
PR Newswire
17/01/2025

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP…

Bagsværd, Denmark, 17 January 2025– Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 randomised adults with obesity. All treatment arms were in conjunction with lifestyle intervention.The trial achieved its primary endpoint by demonstrating a...
Nasdaq GlobeNewswire
17/01/2025

IM Cannabis Announces Change of Auditors

About IM Cannabis Corp. About IM Cannabis Corp. IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients inIsraelandGermany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel andGermany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced...
PR Newswire
17/01/2025

Junshi Biosciences Announces Toripalimab's Approval in Australia

This NCE application was submitted under Project Orbis. Project Orbis, initiated and advocated by the Oncology Center of Excellence (OCE) of the US Food and Drug Administration (the “FDA”), provides a collaborative mechanism and framework among the FDA and regulatory authorities in other countries and regions allowing different regulatory authorities to jointly review the applications for registration of oncology drugs. Toripalimab was the first domestic oncology drug included in Project...
Nasdaq GlobeNewswire
17/01/2025

Systemair finalizes the purchase of the final 10 percent of the shares in…

For further information contact: Roland Kasper, CEO, + 46 73 094 40 13Anders Ulff, CFO, + 46 70 577 40 09 For further information contact: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair in brief Systemair is a leading ventilation company operating in 51 countries inEurope,North America, theMiddle East,Asia,AustraliaandAfrica. The company had a turnover ofSEK 12.3 billionin the 2023/24 financial year and employs...
PR Newswire
17/01/2025

IBA announces Chief Financial Officer transition

Louvain-La-Neuve, Belgium, January 17, 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that Soumya Chandramouli will be stepping down from her role as Chief Financial Officer (“CFO”), effective 31 January 2025. Henri de Romrée, Deputy CEO, will oversee the financial direction at Group level until a new CFO has been appointed...
Nasdaq GlobeNewswire
17/01/2025

New study highlights effectiveness and cost benefits of Myriad™ in lower limb…

A staggering 95% of patients enrolled in the study had at least one risk factor for lower limb amputation, and 55% had 3 or more predictive risk factors for amputation. A staggering 95% of patients enrolled in the study had at least one risk factor for lower limb amputation, and 55% had 3 or more predictive risk factors for amputation. Lower limb amputation has the potential to severely impact quality of life, with the 5-year mortality rate for patients receiving a lower limb amputation...
PR Newswire
17/01/2025

Illuccix® Receives European Approval

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine commented, "We are delighted by this positive outcome, setting the stage for a European commercial launch of Illuccix. This clinically important prostate cancer imaging modality is currently recommended in international clinical practice guidelines including European Association of Urology (EAU) and European Society for Medical Oncology (ESMO)." Kevin Richardson, Chief Executive Officer, Telix Precision Medicine...
PR Newswire
16/01/2025

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial…

"The enrolment of the first patient in the MAGICAL BTK trial represents an important stride toward improving the standard of care for below-the-knee disease in patients with peripheral artery disease," said Dr. Prakash Krishnan, MD, Icahn School of Medicine at Mount Sinai. "Sirolimus-coated balloon technology has the potential to significantly enhance limb salvage and patient quality of life. I am honored to be part of this landmark study and look forward to the meaningful…
PR Newswire
16/01/2025

Virbac: Strong annual revenue growth of +13.6% supported by dynamic organic…

Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%)Press release issued on January 16, 2025 after market close at 5:45pm CETKEY FIGURESAnnual Revenue 2024 €1,397.5 millionGrowth at constant exchange ratesand scope 1 +7.5%of whichcompanion animals +10.7%farm animals +2.4%Growth at constantexchange rates 2 +13.6% ...
Nasdaq GlobeNewswire
16/01/2025

Cardiovascular Devices Market to Hit USD 110.39 Billion by 2029 with 7.3% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72205881 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72205881 Browse in-depth TOC on "Cardiovascular Devices Market" 380 - Tables150 - Figures250 - Pages Based on Product type, the cardiovascular devices market has been segmented into cardiac imaging & diagnostic device, Cardiac rhythm management device, Interventional cardiology device, Cardiac...
PR Newswire
16/01/2025
Altri  Comunicati